Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcitriol Monotherapy for X-Linked Hypophosphatemia
NCT03748966Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2019
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of calcitriol in X-linked hypophosphatemia (XLH) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Change in Serum Phosphate at 12 months, Change From Baseline in TmP/GFR at 12 months and 2 more. Started Mar 2019; status: completed.
02
Drugs
calcitriol
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT03748966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748966.